



Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology
Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Uro-Oncology Clinic**

875 Blake Wilbur Dr Clinic E

MC 6513

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 736-1640

Bio

BIO

Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practiced in this field now for more than 20 years . She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit . She serves as the Vice chair on the National Comprehensive Cancer Center (NCCN) panel for prostate cancer and has coauthored numerous publications and book chapters. She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.

CLINICAL FOCUS

- Cancer > Urologic Oncology
- Bladder Cancer
- Bladder Cancer - Medical Oncology
- Germ Cell Tumors
- Germ Cell Tumors - Medical Oncology
- Germ Cell Tumors - Urologic Oncology
- Kidney Cancer
- Kidney Cancer - Medical Oncology
- Male Cancers - Penile
- Male Cancers - Prostate
- Male Cancers - Testicular
- Oncology (Cancer)
- Penile Cancer
- Prostate Cancer
- Prostate Cancer - Medical Oncology

- Testicular Tumors
- Testicular Tumors - Medical Oncology
- Ureteral Cancer
- Ureteral Cancer - Medical Oncology
- Urethral Cancer
- Urethral Cancer - Medical Oncology
- Urologic Cancers
- Urologic Cancers - Medical Oncology
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Oncology
- Professor - University Medical Line (By courtesy), Urology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- DSMC Vice Chair, Stanford University, (2002-2019)
- Prostate Panel member, NCCN, (2002- present)
- Unit based Medical Director, Stanford Hospital, (2012- present)

HONORS AND AWARDS

- Oncology Teaching award, Stanford University (2002)
- Medicine Chief residents teaching award, Stanford University (2003)
- Oncology clinical fellows teaching award, Stanford University (2003)
- Oncology Clinical Fellows teaching award, Stanford University (2004)
- Oncology Clinical Fellows Teaching award, Stanford University (2005)
- Oncology Clinical Fellows Teaching award, Stanford University (2006)
- Oncology Clinical Fellows teaching award, Stanford University (2007)
- Oncology Clinical Fellows Teaching award, Stanford University (2008)
- Oncology Clinical Fellows Teaching award, Stanford University (2009)
- Oncology Clinical Fellows teaching award, Stanford University (2012)
- Oncology Clinical Fellows Teaching award, Stanford University (2013)
- Saul Rosenberg clinical fellows teaching award, Stanford University (2015)
- Saul Rosenberg clinical Fellows teaching award, Stanford University (2016)
- Denise O'Leary Clinical Excellence Award, Stanford Hospital Board of Directors (2018)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2009)
- Fellowship: UCSF Hematology and Medical Oncology Fellowship (1994) CA
- Residency: Rochester Regional Health at Unity Hospital Internal Medicine Residency (1991) NY
- Medical Education: Madras University Medicine (1985) India

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

The Genito-Urinary Multidisciplinary tumor board at Stanford specializes in taking care of patients with prostate cancer, renal cancer, testicular and bladder cancer. Patients are seen at different stages of their tumor. A multidisciplinary approach is used. A variety of clinical trials are available to patients. Phase II trials using unique combination of chemotherapy agents, antiangiogenic drugs, novel agents are being explored. Co-operative group participation through ECOG is also available

CLINICAL TRIALS

- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours, Recruiting
- Phase I Open-Label Study of BMS-986460 in Metastatic Castration-Resistant Prostate Cancer, Recruiting
- Phase III MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in mCRPC Progressed After NHA, Recruiting
- Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body, Recruiting
- 18 F-fluoride PET/CT versus 99Tc-MDP Scanning for Detecting Bone Metastases, Not Recruiting
- A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial of Sutent +/- Bevacizumab, Not Recruiting
- A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC), Not Recruiting
- A Phase II Trial of Calcitriol and Naproxen in Patients with Recurrent Prostate Cancer, Not Recruiting
- Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in RCC, Not Recruiting
- Early Access Protocol Abiraterone Acetate in Progressed Metastatic CRPC After Taxane-Based Chemo, Not Recruiting
- EMERGE-201: Phase II Lurbinectedin Efficacy in Advanced or Metastatic Solid Tumors, Not Recruiting
- Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI, Not Recruiting
- Expanded Access Atezolizumab in Locally Advanced /Metastatic Urothelial Carcinoma, Not Recruiting
- Expanded Access MDV3100 in Progressive CR Prostate CA Previously Treated with Docetaxel-based Chemo, Not Recruiting
- First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy, Not Recruiting
- Fulvestrant in Hormone Refractory Prostate Cancer, Not Recruiting
- Immunologic Profile in Newly Dx Medulloblastoma at Initial Dx and During Standard RT and Chemo, Not Recruiting
- MAP Cohort Tx Plan CAAA617A12001M to Provide Access to 177Lu-PSMA-617 in mCRPC, Not Recruiting
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy, Not Recruiting
- Phase 1b Cabozantinib (XL184) +/- Atezolizumab in Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Phase 1b/2 AMG 102 + Mitoxantrone & Prednisone for Previously Treated Castrate Resistant Prostate CA, Not Recruiting
- Phase 2 Cisplatin/Gemcitabine +/- VX-970 in Metastatic Urothelial Carcinoma, Not Recruiting
- Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy, Not Recruiting
- Phase I ASG-22CE in Metastatic Urothelial Cancer & Other Malignant Solid Tumors Expressing Nectin-4, Not Recruiting
- Phase I AV-951 with Temozolomide for Metastatic Renal Cell Carcinoma, Not Recruiting
- Phase I CC-94676 in Metastatic Castration-Resistant Prostate Cancer, Not Recruiting
- Phase I Sodium Selenite in Combination with Docetaxel in Castration-resistant Prostate Cancer, Not Recruiting
- Phase I XL092 Single-Agent & Combo Therapy in Inoperable Locally Advanced or Metastatic Solid Tumors, Not Recruiting

- Phase I/Ib Ciforadenant Single Agent & Combo w/ Atezolizumab in Selected Incurable Cancers, Not Recruiting
- Phase I/II Anti-CD27 Antibody(Varilumab) + Anti-PD-1(Nivolumab) in Advanced Refractory Solid Tumors, Not Recruiting
- Phase I/II Enfortumab Vedotin(ASG-22CE) +/- Other Anticancer Therapies in Tx of Urothelial Cancer, Not Recruiting
- Phase I/II Glutaminase Inhibitor CB-839 +/- Nivolumab in Melanoma, Renal Cell Carcinoma & NSCLC, Not Recruiting
- Phase I/II HSP90 Inhibitor AT13387 +/- Abiraterone Acetate in Castration-Resistant Prostate Cancer, Not Recruiting
- Phase I/II REGN4336 +/- Cemiplimab in Metastatic Castration-Resistant Prostate Cancer, Not Recruiting
- Phase I/IIA TRC253 (Androgen Receptor Antagonist) in Metastatic Castration-Resistant Prostate Cancer, Not Recruiting
- Phase Ib SGN-75 in combination with Everolimus in CD70-Positive Metastatic Renal Cell Carcinoma , Not Recruiting
- Phase Ib/II Atezolizumab +/- Bacille Calmette-Guerin in High-Risk Non-Muscle-Invasive Bladder Cancer, Not Recruiting
- Phase II Adaptive 2-Stage Study of Weekly AZD4877 for Recurrent Advanced Urothelial CA, Not Recruiting
- Phase II Adjuvant DN24-02 in High Risk HER2+ Urothelial Carcinoma, Not Recruiting
- Phase II AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma, Not Recruiting
- Phase II ARQ 197 +/- Erlotinib in Papillary Renal Cell Carcinoma, Not Recruiting
- Phase II Atezolizumab in Locally Advanced or Metastatic Urothelial Bladder Cancer, Not Recruiting
- Phase II AZD6094 (HMPL-504) in Papillary Renal Cell Carcinoma (PRCC), Not Recruiting
- Phase II BMS-936558 (MDX-1106) in Progressive Advanced/Metastatic RCC with Prior Anti-Angiogenic Tx, Not Recruiting
- Phase II CB-839 + Everolimus vs Placebo + Everolimus in Advanced /Metastatic Renal Cell Carcinoma, Not Recruiting
- Phase II Co-Expression Extrapolation w/Neoadjuvant Chemo in Localized Muscle-Invasive Bladder Cancer, Not Recruiting
- Phase II Dalantercept + Axitinib Compared to Placebo + Axitinib in Advanced Renal Cell Carcinoma, Not Recruiting
- Phase II Durvalumab with Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer, Not Recruiting
- Phase II Enzalutamide vs. Bicalutamide in Prostate Cancer w/ Failed Primary Androgen Deprivation Tx, Not Recruiting
- Phase II Gemcitabine and Cisplatin +/- Cetuximab for Urothelial Carcinoma, Not Recruiting
- Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer, Not Recruiting
- Phase II IPI-504 in Castration-Resistant Prostate Cancer Stratified by Prior Chemotherapy, Not Recruiting
- Phase II Itraconazole in CRPC Post Docetaxel Chemotherapy, Not Recruiting
- Phase II MEDI-522 + Docetaxel/Prednisone/Zoledronic Acid in Metastatic Androgen Ind. Prostate Cancer, Not Recruiting
- Phase II MK-2206 + Bicalutamide in Prostate CA with High-Risk of Progression After Primary Therapy, Not Recruiting
- Phase II Paclitaxel Ifosfamide & Cisplatin vs Bleomycin Etoposide & Cisplatin in Germ Cell Tumors, Not Recruiting
- Phase II Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Urothelial CA w/FGFR Genomic Alterations, Not Recruiting
- Phase II Pazopanib in Combination with Weekly Paclitaxel in Refractory Urothelial Cancer, Not Recruiting
- Phase II RPLND as First-Line Tx in Testicular Seminoma with Isolated Retroperitoneal Disease, Not Recruiting
- Phase II Rucaparib in Locally Advanced or Metastatic Urothelial Carcinoma, Not Recruiting
- Phase II Rucaparib in Metastatic Castration-Resistant Prostate Cancer, Not Recruiting
- Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer, Not Recruiting
- Phase II Sunitinib / Gemcitabine or Sunitinib in Advanced RCC with Sarcomatoid Features, Not Recruiting
- Phase II TroVax (MVA-5T4) + Docetaxel vs Docetaxel in Progressive Hormone Refractory Prostate Cancer, Not Recruiting
- Phase II: Adjuvant Taxotere in High Risk Prostate Cancer Post Prostatectomy & XRT, Not Recruiting
- Phase III 177Lu-PSMA-617 in Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer, Not Recruiting
- Phase III Abiraterone Acetate CB7630+Prednisone for Metastatic Castration-Resistant Prostate Cancer, Not Recruiting

- Phase III Adjuvant Axitinib vs Placebo in High Risk Recurrent Renal Cell Cancer, Not Recruiting
- Phase III Afibercept vs Placebo for Metastatic Androgen-Independent Prostate Cancer, Not Recruiting
- Phase III ARN-509 in Non-metastatic Castration Resistant Prostate Cancer, Not Recruiting
- Phase III Atezolizumab in Combo w/ Cabozantinib vs Cabozantinib Alone in Renal Cell Carcinoma, Not Recruiting
- Phase III Atezolizumab vs Observation as Adjuvant Tx in PD-L1 Selected High Risk Bladder Cancer, Not Recruiting
- Phase III Belzutifan + Pembrolizumab vs Placebo + Pembrolizumab in Adjuvant Tx ccRCC PostNephrectomy, Not Recruiting
- Phase III Cabozantinib (XL184) vs Mitoxantrone + Prednisone in Previously Treated Symptomatic CRPC, Not Recruiting
- Phase III Cabozantinib(XL184) in Combo w/ Atezolizumab vs 2nd Novel Hormonal Therapy(NHT) in (m)CRPC, Not Recruiting
- Phase III Compare Tivozanib in Combo w/ Nivolumab to Tivozanib Monotherapy in Renal Cell Carcinoma, Not Recruiting
- Phase III Darolutamide vs Placebo + Std Androgen Deprivation Tx + Docetaxel in Metastatic Prostate Cancer, Not Recruiting
- Phase III Docetaxel and Prednisone +/- Lenalidomide in Castrate-Resistant Prostate Cancer, Not Recruiting
- Phase III Durvalumab +/- G+C for Neoadjuvant Tx Followed by Durvalumab Alone for Adjuvant Tx in MIBC, Not Recruiting
- Phase III Enfortumab Vedotin + Pembrolizumab vs Gemcitabine & Cisplatin in Muscle-invasive Bladder Cancer, Not Recruiting
- Phase III Gemcitabine, Cisplatin, Bevacizumab vs Gemcitabine, Cisplatin, Placebo in Advanced TCC, Not Recruiting
- Phase III Ipatasertib or Placebo + Abiraterone + Prednisone/Prednisolone in Metastatic CR Prostate Can, Not Recruiting
- Phase III Lenvatinib +/- Everolimus or Pembrolizumab vs Sunitinib Advanced Renal Cell Carcinoma, Not Recruiting
- Phase III MEDI4736 Monotherapy & MEDI4736 +/- Tremelimumab vs SoC ChemoTx in Urothelial Bladder Cancer, Not Recruiting
- Phase III MK-3475 in Muscle Invasive Locally Advanced Urothelial Carcinoma (Ambassador) vs Observation, Not Recruiting
- Phase III Nivolumab + Ipilimumab vs Sunitinib Monotherapy in Untreated Advanced or Metastatic RCC, Not Recruiting
- Phase III Nivolumab (BMS-936558) vs Everolimus in Advanced/Metastatic Clear-Cell Renal Cell Carcinoma, Not Recruiting
- Phase III Pazopanib as Adjuvant Therapy in Localized / Locally Advanced RCC Following Nephrectomy, Not Recruiting
- Phase III Pembrolizumab (MK-3475) in Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy, Not Recruiting
- Phase III PROSTVAC-V/F ± GM-CSF in Asymptomatic or Minimally Symptomatic Metastatic, CRPC, Not Recruiting
- Phase III Roll-Over to Continue Darolutamide Tx in Patients Enrolled in Prior Bayer-Sponsored Studies, Not Recruiting
- Phase III Standard-Dose Combo Chemo or High-Dose Combo Chemo + Stem Cell T-plant in Germ Cell Tumors, Not Recruiting
- Phase III Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer, Not Recruiting
- Pilot Local Tumor Irradiation with Autologous PBMC Infusion for Metastatic Renal Cell Carcinoma, Not Recruiting
- PREVAIL Phase III MDV3100 Chemo-Naïve Metastatic Prostate CA + Failed Androgen Deprivation Therapy, Not Recruiting
- Rollover Protocol to Allow Continued Access to Tivozanib (AV-951) for Other Tivozanib Protocols, Not Recruiting
- Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer, Not Recruiting
- Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer, Not Recruiting
- Study of XL999 in Patients With Metastatic Renal Cell Carcinoma, Not Recruiting
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery, Not Recruiting
- Temeolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer, Not Recruiting
- Treatment of Refractory Metastatic Renal Cell Carcinoma with Bevacizumab and RAD001, Not Recruiting
- Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma, Not Recruiting
- Zoledronic Acid with Intermittent Hormonal Therapy in Patients with Prostate Cancer, Not Recruiting
- Phase II Alternative Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC), Not Specified
- Phase II Probiotic Supplementation in Cancer Patients Receiving Chemo or Tyrosine Kinase Inhibitors, Not Specified

- Phase II SRF617 in Combination with AB928 (Etrumadenant) and AB122 (Zimberelimab) in mCRPC, Not Specified
- Phase III DisitamabVedotin +Pembrolizumab vs Chemotherapy in Advanced/Metastatic UrothelialCarcinoma, Not Specified
- Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer, Not Specified

Publications

PUBLICATIONS

- **Renal Epithelioid Angiomyolipoma: Prognostic Implications of Targeted Immunohistochemical and Molecular Markers in Conjunction with Clinicopathologic Features.** *The American journal of surgical pathology*
Sangoi, A. R., Lobo, A., Jha, S., Kaushal, S., Tiwari, A., Mubeen, A., Humble, R., Potterveld, S. K., Williamson, S. R., Akgul, M., Srinivas, S., Mohanty, S. K.
2025
- **An ultrasensitive method for detection of cell-free RNA.** *Nature*
Nesselbush, M. C., Luca, B. A., Jeon, Y. J., Jabara, I., Meador, C. B., Garofalo, A., Binkley, M. S., Hui, A. B., van 't Erve, I., Xu, N., Shi, W. Y., Liu, K. J., Sugio, et al
2025
- **Outcomes with tandem or triplet autologous stem cell transplant for refractory germ cell tumors.**
Glover, M., Shah, S., Fan, A. C., Srinivas, S., Khaki, A., Johnston, L. J.
LIPPINCOTT WILLIAMS & WILKINS.2025
- **PSA response and survival based on metastatic site in patients with metastatic castration resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).**
Allen, J., Bergstrom, C. P., Song, H., Hoffmann, C., Ruiz, S., Chien, J., Moore, K., Parikh, D., Shah, S., Fan, A. C., Srinivas, S., Iagaru, A., Khaki, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).**
Kelly, W., Srinivas, S., Maly, J., Kilari, D., Hussain, A., Saraiya, B., Siddiqui, B., Monk, P., Chatta, G. S., Narayan, V., Rana, D., Thanigaimani, P., Fang, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS295
- **Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.** *Cancer*
Bryce, A. H., Agarwal, N., Beltran, H., Hussain, M. H., Sartor, O., Shore, N., Antonarakis, E. S., Armstrong, A. J., Calais, J., Carducci, M. A., Dorff, T. B., Efstathiou, J. A., Gleave, et al
2024
- **Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).** *European urology*
Gillesen, S., Turco, F., Davis, I. D., Efstathiou, J. A., Fizazi, K., James, N. D., Shore, N., Small, E., Smith, M., Sweeney, C. J., Tombal, B., Zilli, T., Agarwal, et al
2024
- **Incidence and Pitfalls of Adipose Tissue Encountered in Urinary Bladder Biopsy/Transurethral Resection Specimens.** *International journal of surgical pathology*
Rizkalla, C. N., Srinivas, S., Sangoi, A. R.
2024: 10668969241271957
- **Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.** *The New England journal of medicine*
Apolo, A. B., Ballman, K. V., Sonpavde, G., Berg, S., Kim, W. Y., Parikh, R., Teo, M. Y., Sweis, R. F., Geynisman, D. M., Grivas, P., Chatta, G., Reichert, Z. R., Kim, et al
2024
- **A review of mitotane in the management of adrenocortical cancer.** *The oncologist*
Del Rivero, J., Else, T., Hallanger-Johnson, J., Kiseljak-Vassiliades, K., Raj, N., Reidy-Lagunes, D., Srinivas, S., Gilbert, J., Vaidya, A., Aboujaoude, E., Bancos, I., Tito Fojo, A.

2024

- **Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H**
O'Donnell, P. H., Hoimes, C. J., Rosenberg, J. E., Petrylak, D. P., Mar, N., Barata, P. C., Srinivas, S., Gourdin, T., Henry, E., Bilen, M., George, S., Rao, S., Assikis, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Applying Staging PSMA PET/CT in De Novo Metastatic Hormonal Sensitive Prostate Cancer (mHSPC): A Preliminary Single-Center Retrospective Review of Clinical Outcomes**
Song, H., Xing, J., Duan, H., Davidzon, G., Franc, B., Moradi, F., Srinivas, S., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2024
- **Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning: A Randomized Clinical Trial. *JAMA oncology***
Rodriguez, G. M., Parikh, D. A., Kapphahn, K., Gupta, D. M., Fan, A. C., Shah, S., Srinivas, S., Teuteberg, W., Seevaratnam, B., Asuncion, K., Chien, J., Moore, K., Ruiz, et al
2024
- **Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. *European journal of nuclear medicine and molecular imaging***
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, et al
2024
- **Prostate Cancer, Version 3.2024. *Journal of the National Comprehensive Cancer Network : JNCCN***
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Bitting, R., Chapin, B., Cheng, H. H., D'Amico, A. V., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, et al
2024; 22 (3): 140-150
- **Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. *JU open plus***
Bryce, A. H., Crawford, E. D., Agarwal, N., Hussain, M. H., Beltran, H., Cooperberg, M. R., Petrylak, D. P., Shore, N., Spratt, D. E., Tagawa, S. T., Antonarakis, E. S., Aparicio, A. M., Armstrong, et al
2024; 2 (4)
- **Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. *JU open plus***
Crawford, E. D., Bryce, A. H., Hussain, M. H., Agarwal, N., Beltran, H., Cooperberg, M. R., Petrylak, D. P., Shore, N., Spratt, D. E., Tagawa, S. T., Antonarakis, E. S., Aparicio, A. M., Armstrong, et al
2024; 2 (4)
- **68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. *The Lancet. Oncology***
Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A. M., Vasanawala, S., Srinivas, S., Brooks, J. D., Hancock, S., Iagaru, A.
2024
- **Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer***
Parikh, D. A., Rodriguez, G. M., Ragavan, M., Kerr, E., Asuncion, M. K., Hansen, J., Srinivas, S., Fan, A. C., Shah, S., Patel, M. I.
2024; 32 (3): 161
- **Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma.**
Parikh, M., Pal, S., Frankel, P., Ruel, C., Mortazavi, A., Milowsky, M. I., Vaishampayan, U. N., Lyou, Y., Wang, P., Parikh, R., Teplý, B. A., Dreicer, R., Enamekhoo, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 614
- **AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.**
Apolo, A. B., Ballman, K. V., Sonpavde, G. P., Berg, S. A., Kim, W. Y., Parikh, R., Teo, M., Sweis, R. F., Geynisman, D. M., Grivas, P., Chatta, G. S., Reichert, Z. R., Kim, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: LBA531

- **Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of ¹⁷⁷Lu-PSMA-617 treatment.**
Leonio, M., Ferri, V., Duan, H., Shah, J., Moradi, F., Mari Aparici, C., Franc, B., Davidzon, G., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, A., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 32
- **Total and anatomically contextualized quantitative ¹⁸F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.**
Song, H., Anand, A., Sjostrand, K., Ferri, V., Duan, H., Shah, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Bergstrom, C. P., Fan, A. C., Shah, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 33
- **First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).**
Rathkopf, D. E., Patel, M. R., Choudhury, A., Rasco, D. W., Lakhani, N. J., Hawley, J. E., Aparicio, A., Narayan, V., Srinivas, S., Runcie, K., Emamekhoo, H., Reichert, Z. R., Carducci, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 134
- **Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT)**
Bergstrom, C. P., Song, H., Ruiz, S., Chien, J., Moore, K., Parikh, D., Shah, S., Fan, A. C., Srinivas, S., Iagaru, A., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2024: 86
- **Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC).**
Bolan, P., Hui, G., Low, Y., Gombar, S., Fan, A. C., Parikh, D., Shah, S., Srinivas, S., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2024: 402
- **Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Milowsky, M. I., O'Donnell, P. H., Hoimes, C. J., Petrylak, D. P., Flaig, T. W., Moon, H. H., Friedlander, T. W., Mar, N., McKay, R. R., Srinivas, S., Gravis, G., Ramamurthy, C., Bupathi, et al
2024: JCO2301547
- **A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.** *Future oncology (London, England)*
Hoimes, C. J., Flaig, T. W., Milowsky, M. I., Friedlander, T. W., Bilen, M. A., Gupta, S., Srinivas, S., Merchan, J. R., McKay, R. R., Petrylak, D. P., Sasse, C., Moreno, B. H., Yu, et al
2023
- **Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
O'Donnell, P. H., Milowsky, M. I., Petrylak, D. P., Hoimes, C. J., Flaig, T. W., Mar, N., Moon, H. H., Friedlander, T. W., McKay, R. R., Bilen, M. A., Srinivas, S., Burgess, E. F., Ramamurthy, et al
2023: JCO2202887
- **Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes**
Glover, M., Chiang, R. S., Hoerner, C. R., Khan, O. A., Kao, C., Shah, S., Srinivas, S., Fan, A. C., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up**
Gupta, S., Rosenberg, J. E., Mckay, R. R., Flaig, T. W., Petrylak, D. P., Hoimes, C. J., Friedlander, T. W., Bilen, M., Srinivas, S., Burgess, E. F., Merchan, J. R., Tagawa, S. T., Brown, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.**
Flaig, T. W., Rosenberg, J. E., Hoimes, C. J., O'Donnell, P. H., Mar, N., Gourdin, T., Henry, S., Bilen, M., George, S., Barata, P. C., Srinivas, S., Rao, S., Assikis, et al
LIPPINCOTT WILLIAMS & WILKINS.2023

- **Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.** *European journal of cancer (Oxford, England : 1990)*
Gillesen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C. J., Tombal, B., Antonarakis, et al
2023; 185: 178-215
- **Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.**
Khaki, A., Fan, A. C., Shah, S., Parikh, D., Chien, J., Moore, K., Ruiz, S., Haas, D., Fakhoury, L., Del Toro, N., Baker, P., O'Brien, A., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.**
O'Donnell, P. H., Rosenberg, J. E., Hoimes, C. J., Petrylak, D. P., Milowsky, M. I., McKay, R. R., Srinivas, S., Friedlander, T. W., Ramamurthy, C., Bilen, M., Burgess, E. F., Mar, N., Moon, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.**
Milowsky, M. I., O'Donnell, P. H., Hoimes, C. J., Petrylak, D. P., Flaig, T. W., Moon, H. H., Friedlander, T. W., Mar, N., McKay, R. R., Srinivas, S., Gravis, G., Ramamurthy, C., Bupathi, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.** *European urology*
Molina, G. E., Schwartz, B., Srinivas, S., Shah, S., Zaba, L. C.
2023
- **Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D'Amico, A. V., Desai, N., Dorff, T., Eastham, et al
2023; 21 (10): 1067-1096
- **Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.** *European urology*
Gillesen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, et al
2022
- **Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams.** *Targeted oncology*
Shore, N. D., Morgans, A. K., El-Haddad, G., Srinivas, S., Abramowitz, M.
2022
- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022: OP2200128
- **Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Hoimes, C. J., Flaig, T. W., Milowsky, M. I., Friedlander, T. W., Bilen, M. A., Gupta, S., Srinivas, S., Merchan, J. R., McKay, R. R., Petrylak, D. P., Sasse, C., Moreno, B. H., Yu, et al
2022: 101200JCO2201643
- **Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.** *Circulation*
Zhu, H., Galdos, F. X., Lee, D., Waliyany, S., Vivian Huang, Y., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., Srinivas, S., Lin, L. L., Witteles, et al
2022: 101161CIRCULATIONAHA121056730
- **Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).** *The Lancet. Oncology*

Agarwal, N., McGregor, B., Maughan, B. L., Dorff, T. B., Kelly, W., Fang, B., McKay, R. R., Singh, P., Pagliaro, L., Dreicer, R., Srinivas, S., Lorient, Y., Vaishampayan, et al
2022

- **Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.**
Petrylak, D. P., Flaig, T. W., Mar, N., Gourdin, T., Srinivas, S., Rosenberg, J. E., Guseva, M., Yu, Y., Narayanan, S., Hoimes, C. J.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Hong Song, Heying Duan, Caitlyn Harrison, Kip Guja, Negin Hatami, Judy Nguyen, Benjamin Franc, Farshad Moradi, Carina Mari Aparici, Guido Davidzon, Sandy Srinivas and Andrei Iagaru**
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Nguyen, J., Franc, B., Moradi, F., Aparici, C., Davidzon, G., Srinivas, S., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2022
- **Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.**
Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., Kao, C., Shah, S., Srinivas, S., Fan, A. C., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).**
Hoimes, C. J., Flaig, T. W., Srinivas, S., Mar, N., Petrylak, D. P., O'Donnell, P. H., Bilen, M., Sasse, C., Yu, Y., Birrenkott, M., Rosenberg, J. E.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.**
Petrylak, D. P., Flaig, T. W., Mar, N., Gourdin, T., Srinivas, S., Rosenberg, J. E., Guseva, M., Yu, Y., Narayanan, S., Hoimes, C. J.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging** *JOURNAL OF NUCLEAR MEDICINE*
Jadvar, H., Calais, J., Fanti, S., Feng, F., Greene, K. L., Gulley, J. L., Hofman, M., Koontz, B. F., Lin, D. W., Morris, M. J., Rowe, S. P., Royce, T. J., Salami, et al
2022; 63 (1): 59-68
- **NCCN Guidelines Insights: Prostate Cancer, Version 1.2023.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D'Amico, A. V., Desai, N., Dorff, T., Eastham, et al
2022; 20 (12): 1288-1298
- **Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab.** *OncoTargets and therapy*
Chiang, R. S., Glover, M. J., Khaki, A. R., Srinivas, S.
2022; 15: 1259-1269
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Jadvar, H., Calais, J., Fanti, S., Feng, F., Greene, K. L., Gulley, J. L., Hofman, M., Koontz, B. F., Lin, D. W., Morris, M. J., Rowe, S. P., Royce, T. J., Salami, et al
2021
- **Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.** *Journal of patient-reported outcomes*
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., Velazquez, B., Chu, G., Bruzzone, B., Cabot, A., Fisher, G. A., Srinivas, S., Fan, et al
2021; 5 (1): 91
- **Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

- Pal, S. K., McGregor, B., Suarez, C., Tsao, C., Kelly, W., Vaishampayan, U., Pagliaro, L., Maughan, B. L., Lorient, Y., Castellano, D., Srinivas, S., McKay, R. R., Dreicer, et al
2021: JCO2100939
- **To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Srinivas, S., Iagaru, A.
2021
 - **Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.** *JAMA oncology*
Pal, S. K., Frankel, P. H., Mortazavi, A., Milowsky, M., Vaishampayan, U., Parikh, M., Lyou, Y., Weng, P., Parikh, R., Teplý, B., Dreicer, R., Emamekhoo, H., Michaelson, et al
2021
 - **Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma after Previous Platinum-Based Chemotherapy for Metastatic Disease.** *The oncologist*
Wong, R. L., Ferris, L. A., Do, O. A., Holt, S. K., Ramos, J. D., Crabb, S. J., Sternberg, C. N., Bellmunt, J., Ladoire, S., De Giorgi, U., Harshman, L. C., Vaishampayan, U. N., Necchi, et al
2021
 - **Study EV-103: Update on durability results and long term outcome of enfortumab vedotin plus pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).**
Friedlander, T. W., Milowsky, M. I., Bilen, M., Srinivas, S., McKay, R. R., Flaig, T. W., Hoimes, C. J., Balar, A., Henry, E., Petrylak, D. P., Sasse, C., Kataria, R. S., Yu, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
 - **Evolving oncology provider perspectives on care delivery during the COVID-19 pandemic.**
Parikh, D., Ragavan, M., Srinivas, S., Garrigues, S., Rosenthal, E., Patel, M. I.
LIPPINCOTT WILLIAMS & WILKINS.2021
 - **A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.**
Pal, S. K., Mortazavi, A., Milowsky, M. I., Vaishampayan, U. N., Parikh, M., Lyou, Y., Wang, P., Parikh, R., Teplý, B. A., Dreicer, R., Emamekhoo, H., Michaelson, M., Hoimes, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
 - **Management of Metastatic Castration-Resistant Prostate Cancer** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Srinivas, S.
2021; 19 (5.5): 614-616
 - **PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., Hancock, S., Shah, S. A., Srinivas, S., Swift, P., Moradi, F., Davidzon, G. A., Iagaru, et al
2021
 - **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*
Waliyany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137-39
 - **Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens.**
Wong, R., Ferris, L., Do, O. A., Holt, S. K., Ramos, J., Crabb, S. J., Sternberg, C. N., Bellmunt, J., Ladoire, S., De Giorgi, U., Harshman, L. C., Vaishampayan, U. N., Necchi, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
 - **Addressing financial toxicity in urologic oncology patients.**
Parikh, D., Srinivas, S., Kerr, E., Patel, M.
LIPPINCOTT WILLIAMS & WILKINS.2021

- **NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Schaeffer, E., Srinivas, S., Antonarakis, E. S., Armstrong, A. J., Bekelman, J. E., Cheng, H., D'Amico, A. V., Davis, B. J., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, et al
2021; 19 (2): 134–43
- **Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens.** *Clinical genitourinary cancer*
Do, O. A., Ferris, L. A., Holt, S. K., Ramos, J. D., Harshman, L. C., Plimack, E. R., Crabb, S. J., Pal, S. K., De Giorgi, U., Ladoire, S., Baniel, J., Necchi, A., Vaishampayan, et al
2020
- **Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.** *Cancer medicine*
Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., Tsai, J., Fang, J., Waldeck, A. R., Simmons, S. J.
2020
- **Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.** *Cancer*
Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Plimack, E. R., Procopio, G., McDermott, D. F., Castellano, D., Choueiri, T. K., Donskov, et al
2020
- **Recent Developments in the Management of Advanced Prostate Cancer**
Srinivas, S.
HARBORSIDE PRESS.2020: 969–72
- **Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.** *Urologic oncology*
Bhambhani, H. P., Zamora, A., Shkolyar, E., Prado, K., Greenberg, D. R., Kasman, A. M., Liao, J., Shah, S., Srinivas, S., Skinner, E. C., Shah, J. B.
2020
- **Physician preferences for non-metastatic castration-resistant prostate cancer treatment.** *BMC urology*
Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., Horodniceanu, E., Waldeck, A. R., Simmons, S. J.
2020; 20 (1): 73
- **Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.**
Mar, N., Friedlander, T. W., Hoimes, C. J., Flaig, T. W., Bilen, M., Balar, A., Henry, E., Srinivas, S., Rosenberg, J. E., Petrylak, D., Burgess, E., Merchan, J. R., Tagawa, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.**
Rosenberg, J. E., Flaig, T. W., Friedlander, T. W., Milowsky, M., Srinivas, S., Petrylak, D., Merchan, J. R., Bilen, M., Carret, A., Yuan, N., Sasse, C., Hoimes, C. J.
AMER SOC CLINICAL ONCOLOGY.2020
- **Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.**
Agarwal, N., Loriot, Y., McGregor, B., Dreicer, R., Dorff, T. B., Maughan, B., Kelly, W., Pagliaro, L. C., Srinivas, S., Squillante, C., Vaishampayan, U., N., Wang, E. W., Curran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.**
Dudani, S., Gan, C., Wells, C., Bakouny, Z., Dizman, N., Pal, S. K., Wood, L., Kollmannsberger, C. K., Szabados, B., Powles, T., Beuselinck, B., Donskov, F., Hansen, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.**
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B., Moradi, F., Aparici, C., Davidzon, G., Srinivas, S., Iagaru, A.
AMER SOC CLINICAL ONCOLOGY.2020
- **Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens.**

- Do, O. A., Ferris, L., Holt, S. K., Ramos, J., Harshman, L. C., Plimack, E. R., Crabb, S. J., Pal, S. K., De Giorgi, U., Ladoire, S., Baniel, J., Necchi, A., Vaishampayan, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.**
Baratto, L., Song, H., Duan, H., Aparici, C., Davidzon, G., Moradi, F., Srinivas, S., Iagaru, A.
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era.**
Parikh, D., Serrato, P., Srinivas, S., Ryckman, T., Salomon, J., Goldhaber-Fiebert, J. D.
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.** *European urology*
Bhindi, B., Graham, J., Wells, J. C., Bakouny, Z., Donskov, F., Fraccon, A., Pasini, F., Lee, J. L., Basappa, N. S., Hansen, A., Kollmannsberger, C. K., Kanesvaran, R., Yuasa, et al
2020
 - **Prostate Cancer Brain Metastases: A Single-Institution Experience.** *World neurosurgery*
Bhambhani, H. P., Greenberg, D. R., Srinivas, S., Gephart, M. H.
2020
 - **Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma**
Rosenberg, J. E., Flaig, T. W., Friedlander, T. W., Milowsky, M. I., Srinivas, S., Petrylak, D., Merchan, J. R., Bilen, M., Carret, A., Yuan, N., Sasse, C., Hoimes, C. J.
AMER SOC CLINICAL ONCOLOGY.2020
 - **Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study**
Agarwal, N., Loriot, Y., McGregor, B., Dreicer, R., Dorff, T. B., Maughan, B., Kelly, W., Pagliaro, L. C., Srinivas, S., Squillante, C., Vaishampayan, U. N., Liu, Y., Curran, et al
AMER SOC CLINICAL ONCOLOGY.2020
 - **Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with > 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)**
Motzer, R. J., Tsykodi, S. S., Escudier, B., Oudard, S., Hammers, H. J., McDermott, D. F., George, S., Castellano, D., Choueiri, T. K., Alva, A., Richardet, M., Plimack, E. R., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2020
 - **Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial**
Grivas, P., Loriot, Y., Feyerabend, S., Morales-Barrera, R., Teo, M., Vogelzang, N. J., Grande, E., Zakharia, Y., Adra, N., Alva, A., Necchi, A., Gupta, S., Josephs, et al
AMER SOC CLINICAL ONCOLOGY.2020
 - **EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Rosenberg, J. n., Sridhar, S. S., Zhang, J. n., Smith, D. n., Ruether, D. n., Flaig, T. W., Baranda, J. n., Lang, J. n., Plimack, E. R., Sangha, R. n., Heath, E. I., Merchan, J. n., Quinn, et al
2020: JCO1902044
 - **Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Tripathi, A. n., Supko, J. G., Gray, K. P., Melnick, Z. n., Regan, M. M., Taplin, M. E., Choudhury, A. D., Pomerantz, M. M., Bellmunt, J. n., Yu, C. n., Sun, Z. n., Srinivas, S. n., Kantoff, et al
2020
 - **Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.** *Journal of the American Academy of Dermatology*
Hirotsu, K. E., Rana, J. n., Wang, J. Y., Raghavan, S. S., Rieger, K. E., Srinivas, S. n., Fan, A. C., Kwong, B. Y., Novoa, R. A., Zaba, L. n.
2020

- **Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.** *The Journal of urology*
Sonpavde, G. n., Manitz, J. n., Gao, C. n., Tayama, D. n., Kaiser, C. n., Hennessy, D. n., Makari, D. n., Gupta, A. n., Abdullah, S. E., Niegisch, G. n., Rosenberg, J. E., Bajorin, D. F., Grivas, et al
2020: 101097JU0000000000001199
- **Impact of mortality reviews on supportive care utilization, end-of-life care, and inpatient mortality.**
Karimi, Y., Divi, V., Srinivas, S., Smith, A., Hansen, J., Tokareva, I., Tulu, Z., Hedlin, H., Fronk, J., Rosenthal, E., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2019
- **The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer** *ONCOLOGIST*
Bamias, A., Tzannis, K., Bamia, C., Harshman, L. C., Crabb, S., Plimack, E. R., Pal, S., De Giorgi, U., Ladoire, S., Theodore, C., Agarwal, N., Yu, E. Y., Niegisch, et al
2019; 24 (10): 1348–55
- **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**
Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Patient and caregiver benefit-risk preferences for non metastatic castration-resistant prostate cancer treatment (nmCRPC).**
Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., Tsai, J., Fang, J., Waldeck, A., Simmons, S. J.
AMER SOC CLINICAL ONCOLOGY.2019
- **Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor** *JACC: CARDIOONCOLOGY*
Waliyany, S., Sainani, K. L., Park, L. S., Zhang, C., Srinivas, S., Witteles, R. M.
2019; 1 (1): 24–36
- **Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.** *JACC. CardioOncology*
Waliyany, S., Sainani, K. L., Park, L. S., Zhang, C. A., Srinivas, S., Witteles, R. M.
2019; 1 (1): 24-36
- **ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma**
Grivas, P., Teo, M., Vogelzang, N., Alva, A., Zakharia, Y., Adra, N., Drakaki, A., Hussain, A., Morales-Barrera, R., Necchi, A., Rodriguez-Vida, A., Feyerabend, S., Gupta, et al
AMER ASSOC CANCER RESEARCH.2019
- **Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis** *FUTURE ONCOLOGY*
Abogunrin, S., Ashaye, A. O., Cappelleri, J. C., Clair, A. G., Fahrbach, K., Ramaswamy, K., Serfass, L., Srinivas, S., Thomaidou, D., Zanotti, G.
2019; 15 (18): 2175–90
- **Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).**
Feldman, D. R., Hu, J. S., Patil, S., Reuter, V. E., Srinivas, S., Stadler, W., Costello, B., Milowsky, M. I., Appleman, L., Dorff, T. B., Bromberg, M., Joseph, G., Funt, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.**
Sonpavde, G., Manitz, J., Gao, C., Hennessy, D., Makari, D., Niegisch, G., Rosenberg, J. E., Bajorin, D. F., Grivas, P., Apolo, A. B., Dreicer, R., Hahn, N. M., Galsky, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.**
Bhindi, B., Graham, J., Wells, C., Donskov, F., Pasini, F., Lee, J., Basappa, N. S., Hansen, A., Wood, L., Kollmannsberger, C. K., Kanesvaran, R., Yuasa, T., Ernst, et al
AMER SOC CLINICAL ONCOLOGY.2019

- **Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC).**
Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., Horodniceanu, E., Waldeck, R., Simmons, S. J.
AMER SOC CLINICAL ONCOLOGY.2019
- **Prostate Cancer, Version 2.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D'Amico, A., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E., Hurwitz, M., Ippolito, et al
2019; 17 (5): 479–505
- **Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis.** *Future oncology (London, England)*
Abogunrin, S., Ashaye, A. O., Cappelleri, J. C., Clair, A. G., Fahrback, K., Ramaswamy, K., Serfass, L., Srinivas, S., Thomaidou, D., Zanotti, G.
2019
- **Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT** *CLINICAL NUCLEAR MEDICINE*
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Torihara, A., Hatami, N., Yohannan, T. K., Mitra, E.
2019; 44 (4): E272–E279
- **Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study** *LANCET ONCOLOGY*
Changa, N., Xie, W., Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., Balakrishnan, A., Bowman, I., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, et al
2019; 20 (4): 581–90
- **The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.** *The oncologist*
Bamias, A., Tzannis, K., Bamia, C., Harshman, L. C., Crabb, S., Plimack, E. R., Pal, S., De Giorgi, U., Ladoire, S., Theodore, C., Agarwal, N., Yu, E. Y., Niegisch, et al
2019
- **Application of pharmacoeconomics to formulary management in a health system setting** *AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY*
Studdert, A. L., Gong, C. L., Srinivas, S., Chin, A. L., Deresinski, S.
2019; 76 (6): 381–86
- **Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.**
Apolo, A. B., Rosenberg, J. E., Kim, W. Y., Chen, R. C., Sonpavde, G., Srinivas, S., Mortazavi, A., Watt, C., Mallek, M., Graap, K., Diaz, C., Odegaard, M., Ballman, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis** *EUROPEAN UROLOGY FOCUS*
Necchi, A., Mariani, L., Lo Vullo, S., Yu, E. Y., Woods, M. E., Wong, Y., Harshman, L. C., Alva, A., Sternberg, C. N., Bamias, A., Grivas, P., Koshkin, V. S., Roghmann, et al
2019; 5 (2): 242–49
- **Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).**
Rosenberg, J. E., Sridhar, S. S., Zhang, J., Smith, D. C., Ruether, J. D., Flaig, T. W., Baranda, J., Lang, J., Plimack, E. R., Sangha, R. S., Heath, E. I., Merchan, J. R., Quinn, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).**
Grivas, P., Vogelzang, N. J., Alva, A., Feyerabend, S., Lortiot, Y., Necchi, A., Gupta, S., Josephs, D., Rodriguez-Vida, A., Srinivas, S., Zakharia, Y., Wride, K., Thomas, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.** *The Lancet. Oncology*
Martinez Chanza, N., Xie, W., Asim Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., Balakrishnan, A., Bowman, I. A., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, et al
2019

- **Application of pharmacoeconomics to formulary management in a health system setting.** *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists*
Studdert, A. L., Gong, C. L., Srinivas, S., Chin, A. L., Deresinski, S.
2019; 76 (6): 381-386
- **Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.** *Clinical nuclear medicine*
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., Yohannan, T. K., Mitra, E.
2019
- **Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma.** *Cancers*
Chen, V. J., Hernandez-Meza, G. n., Agrawal, P. n., Zhang, C. A., Xie, L. n., Gong, C. L., Hoerner, C. R., Srinivas, S. n., Oermann, E. K., Fan, A. C.
2019; 11 (7)
- **Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study** *EUROPEAN UROLOGY FOCUS*
Necchi, A., Pond, G. R., Smaldone, M. C., Pal, S. K., Chan, K., Wong, Y., Viterbo, R., Sonpavde, G., Harshman, L. C., Crabb, S., Alva, A., Chowdhury, S., De Giorgi, et al
2018; 4 (6): 937-45
- **Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma** *JOURNAL OF UROLOGY*
Sonpavde, G. P., Mariani, L., Lo Vullo, S., Raggi, D., Giannatempo, P., Bamias, A., Crabb, S. J., Bellmunt, J., Yu, E. Y., Niegisch, G., Vaishampayan, U. N., Theodore, C., Berthold, et al
2018; 200 (6): 1207-14
- **Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma** *JOURNAL OF ONCOLOGY PHARMACY PRACTICE*
Srinivas, S., Stein, D., Teltsch, D. Y., Tao, S., Cisar, L., Ramaswamy, K.
2018; 24 (8): 574-83
- **Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium** *CANCER*
Yip, S. M., Wells, C., Moreira, R., Wong, A., Srinivas, S., Beuselinck, B., Porta, C., Sim, H., Ernst, D., Rini, B. I., Yuasa, T., Basappa, N. S., Kanesvaran, et al
2018; 124 (18): 3677-83
- **Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Dietrich, B., Siefker-Radtke, A. O., Srinivas, S., Yu, E. Y.
2018: 342-53
- **Therapeutic benefit of empiric drug sequencing in metastatic renal cell carcinoma**
Chen, V., Gong, C., Hoerner, C. R., Zhang, C. A., Srinivas, S., Fan, A. C.
AMER SOC CLINICAL ONCOLOGY.2018
- **Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).**
Feldman, D. R., Hu, J., Srinivas, S., Stadler, W., Costello, B., Appleman, L., Milowsky, M. I., Patil, S., Bromberg, M., Nolan, P., Dorff, T. B., Reuter, V. E., Al-Ahmadie, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).**
Rosenberg, J. E., Sridhar, S. S., Zhang, J., Smith, D. C., Ruether, J. D., Flaig, T. W., Baranda, J., Lang, J., Plimack, E. R., Sangha, R. S., Heath, E. I., Merchan, J. R., Quinn, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo (R) in mCRPC Patients**
Song, H., Yohannan, T., Srinivas, S., Vasanawala, S., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2018
- **CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (vol 72, pg 962, 2017)** *EUROPEAN UROLOGY*

- Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, et al
2018; 73 (4): E116–E118
- **Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population** *CLINICAL GENITOURINARY CANCER*
Necchi, A., Pond, G. R., Pal, S. K., Agarwal, N., Bowles, D. W., Plimack, E. R., Yu, E. Y., Ladoire, S., Baniel, J., Crabb, S., Niegisch, G., Srinivas, S., Berthold, et al
2018; 16 (2): E483–E490
 - **Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors**
Kunder, C., Imae, Y., Srinivas, S., Fan, A. C.
NATURE PUBLISHING GROUP.2018: 703
 - **Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors**
Kunder, C., Imae, Y., Srinivas, S., Fan, A. C.
NATURE PUBLISHING GROUP.2018: 703
 - **Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study**
Necchi, A., Pond, G., Plimack, E. R., Niegisch, G., Yu, E. Y., Pal, S. K., Bamias, A., Agarwal, N., Alva, A., Srinivas, S., Crabb, S. J., Vaishampayan, U. N., Bowles, et al
AMER SOC CLINICAL ONCOLOGY.2018
 - **Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.**
Petrylak, D., Smith, D. C., Flaig, T. W., Zhang, J., Sridhar, S. S., Ruether, J. D., Plimack, E. R., Merchan, J. R., Quinn, D. I., Kilari, D., Srinivas, S., Baranda, J., Lang, et al
AMER SOC CLINICAL ONCOLOGY.2018
 - **Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).**
Stukalin, I., Wells, J., Graham, J., Yuasa, T., Beuselinck, B., Kollmannsberger, C. K., Ernst, D., Agarwal, N., Le, T., Donskov, F., Hansen, A., Bjamason, G. A., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2018
 - **Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.**
Xie, W., DiNatale, R., Hakimi, A., Donskov, F., Porta, C., Reaume, M., Basappa, N. S., Hansen, A., Rini, B. I., Beuselinck, B., Bjamason, G. A., Srinivas, S., Brugarolas, et al
AMER SOC CLINICAL ONCOLOGY.2018
 - **Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.**
Necchi, A., Mariani, L., Lo Vullo, S., Raggi, D., Giannatempo, P., Bamias, A., Crabb, S. J., Bellmunt, J., Yu, E. Y., Niegisch, G., Vaishampayan, U. N., Theodore, C., Berthold, et al
AMER SOC CLINICAL ONCOLOGY.2018
 - **New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.**
Pond, G., Niegisch, G., Rosenberg, J. E., Dreicer, R., Powles, T., Necchi, A., Wei, X. X., Grivas, P., Balar, A., Galsky, M. D., Srinivas, S., Choueiri, T. K., Bellmunt, et al
AMER SOC CLINICAL ONCOLOGY.2018
 - **Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease** *RESEARCH AND REPORTS IN UROLOGY*
Dietrich, B., Srinivas, S.
2018; 10: 7–16
 - **Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)** *KIDNEY CANCER*
Stukalin, I., Wells, J., Fraccon, A., Pasini, F., Porta, C., Lalani, A. A., Srinivas, S., Bowman, I., Brugarolas, J., Lee, J., Donskov, F., Beuselinck, B., Bamias, et al
2018; 2 (1): 31-36

- **Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.** *European urology focus*
Necchi, A., Pond, G. R., Smaldone, M. C., Pal, S. K., Chan, K., Wong, Y., Viterbo, R., Sonpavde, G., Harshman, L. C., Crabb, S., Alva, A., Chowdhury, S., De Giorgi, et al
2018; 4 (6): 937–45
- **Recommendations for the Management of Rare Kidney Cancers** *EUROPEAN UROLOGY*
Giles, R. H., Choueiri, T. K., Heng, D. Y., Albiges, L., Hsieh, J. J., Linehan, W., Pal, S., Maskens, D., Paseman, B., Jonasch, E., Malouf, G., Molina, A. M., Pickering, et al
2017; 72 (6): 974–83
- **Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm** *JOURNAL OF CLINICAL ONCOLOGY*
Tandstad, T., Kollmannsberger, C. K., Roth, B. J., Jeldres, C., Gillessen, S., Fizazi, K., Daneshmand, S., Lowrance, W. T., Hanna, N. H., Albany, C., Foster, R., Cedermark, G., Feldman, et al
2017; 35 (31): 3525-+
- **Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma** *EUROPEAN UROLOGY*
Pal, S. K., Sonpavde, G., Agarwal, N., Vogelzang, N. J., Srinivas, S., Haas, N. B., Signoretti, S., McGregor, B. A., Jones, J., Lanman, R. B., Banks, K. C., Choueiri, T. K.
2017; 72 (4): 557–64
- **Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study** *JAMA ONCOLOGY*
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H., Friedlander, T., Hoimes, C. J., Lee, J., Ong, M., Sridhar, S. S., Vogelzang, N. J., Fishman, M. N., Zhang, J., Srinivas, et al
2017; 3 (9): e172411
- **Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.** *European urology focus*
Necchi, A., Mariani, L., Lo Vullo, S., Yu, E. Y., Woods, M. E., Wong, Y., Harshman, L. C., Alva, A., Sternberg, C. N., Bamias, A., Grivas, P., Koshkin, V. S., Roghmann, et al
2017
- **Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category** *EUROPEAN UROLOGY*
Davis, I. D., Xie, W., Pezaro, C., Donskov, F., Wells, J. C., Agarwal, N., Srinivas, S., Yuasa, T., Beuselinck, B., Wood, L. A., Ernst, D. S., Kanesvaran, R., Knox, et al
2017; 71 (6): 970-978
- **Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.** *European urology*
Davis, I. D., Xie, W., Pezaro, C., Donskov, F., Wells, J. C., Agarwal, N., Srinivas, S., Yuasa, T., Beuselinck, B., Wood, L. A., Ernst, D. S., Kanesvaran, R., Knox, et al
2017; 71 (6): 970-978
- **Economic burden of empiric drug utilization in metastatic renal cell carcinoma emphasizes the need for early biomarkers of response.**
Chen, V., Gong, C., Zhang, C. A., Srinivas, S., Lee, H. E., Fan, A. C.
AMER SOC CLINICAL ONCOLOGY.2017
- **Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).**
Hahn, N. M., Powles, T., Massard, C., Arkenau, H., Friedlander, T. W., Holmes, C. J., Lee, J., Ong, M., Sridhar, S. S., Vogelzang, N. J., Fishman, M. N., Zhang, J., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).**
Bosse, D., Xie, W., Wells, C., Lalani, A. A., Donskov, F., Bent, A., Sim, H., Beuselinck, B., Bamias, A., Porta, C., Vaishampayan, U. N., Pal, S. K., Agarwal, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).**

- Bosse, D., Xie, W., Wells, C., Lalani, A. A., Donskov, F., Bent, A., Sim, H., Beuselinck, B., Bamias, A., Porta, C., Vaishampayan, U. N., Pal, S. K., Agarwal, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Characterizing the outcomes of metastatic papillary renal cell carcinoma** *CANCER MEDICINE*
Wells, J. C., Donskov, F., Fracon, A. P., Pasini, F., Bjarnason, G. A., Beuselinck, B., Knox, J. J., Rha, S. Y., Agarwal, N., Bowman, I. A., Lee, J., Pal, S. K., Srinivas, et al
2017; 6 (5): 902-909
 - **Automated bone scan index as a prognostic tool in prostate cancer patients with bone metastasis**
Park, S., Srinivas, S., Mitra, E.
SOC NUCLEAR MEDICINE INC.2017
 - **Bone scan index as a new imaging biomarker in response assessment of prostate cancer patients with bone metastasis**
Park, S., Srinivas, S., Mitra, E.
SOC NUCLEAR MEDICINE INC.2017
 - **Consolidative Radiotherapy in Metastatic Urothelial Cancer.** *Clinical genitourinary cancer*
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., Srinivas, S.
2017
 - **CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.** *European urology*
Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, et al
2017
 - **Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.**
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H., Friedlander, T. W., Hoimes, C., Lee, J., Ong, M., Sridhar, S. S., Vogelzang, N. J., Fishman, M. N., Zhang, J., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2017
 - **Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)** *EUROPEAN UROLOGY*
Necchi, A., Sonpavde, G., Lo Vullo, S., Giardiello, D., Bamias, A., Crabb, S. J., Harshman, L. C., Bellmunt, J., De Giorgi, U., Sternberg, C. N., Cerbone, L., Ladoire, S., Wong, et al
2017; 71 (2): 281-289
 - **Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium** *EUROPEAN UROLOGY*
Wells, J. C., Stukalin, I., Norton, C., Srinivas, S., Lee, J. L., Donskov, F., Bjarnason, G. A., Yamamoto, H., Beuselinck, B., Rini, B. I., Knox, J. J., Agarwal, N., Ernst, et al
2017; 71 (2): 204-209
 - **Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.** *Clinical genitourinary cancer*
de Velasco, G., Xie, W., Donskov, F., Albiges, L., Beuselinck, B., Srinivas, S., Agarwal, N., Lee, J. L., Brugarolas, J., Wood, L. A., Rha, S., Kollmannsberger, C., North, et al
2017
 - **Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial** *LANCET*
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., Dawson, N. A., van der Heijden, M. S., Dreicer, et al
2017; 389 (10064): 67-76
 - **Incorporating VEGF-targeted therapy in advanced urothelial cancer** *THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY*
Narayanan, S., Srinivas, S.
2017; 9 (1): 33-45
 - **Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies.** *Clinical genitourinary cancer*

- Salah, S., Lee, J., Rozzi, A., Kitamura, H., Matsumoto, K., Vis, D. J., Srinivas, S., Morales-Barrera, R., Carles, J., Al-Rimawi, D., Lee, S., Kim, K. H., Izumi, et al
2016
- **The effect of information on preferences for treatments of metastatic renal cell carcinoma.** *Current medical research and opinion*
Mansfield, C., Srinivas, S., Chen, C., Hauber, A. B., Hariharan, S., Matczak, E., Sandin, R.
2016; 32 (11): 1827-1838
 - **Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations** *JOURNAL OF CLINICAL ONCOLOGY*
Albiges, L., Hakimi, A. A., Xie, W., McKay, R. R., Simantov, R., Lin, X., Lee, J., Rini, B. I., Srinivas, S., Bjarnason, G. A., Ernst, S., Wood, L. A., Vaishamayan, et al
2016; 34 (30): 3655-?
 - **Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).** *European urology*
Necchi, A., Sonpavde, G., Lo Vullo, S., Giardiello, D., Bamias, A., Crabb, S. J., Harshman, L. C., Bellmunt, J., De Giorgi, U., Sternberg, C. N., Cerbone, L., Ladoire, S., Wong, et al
2016
 - **Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.** *Clinical genitourinary cancer*
Narayanan, S., Lam, A., Vaishampayan, U., Harshman, L., Fan, A., Pachynski, R., Poushnejad, S., Haas, D., Li, S., Srinivas, S.
2016; 14 (5): 432-437
 - **Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?** *EUROPEAN UROLOGY*
Barbosa, P. V., Thomas, I., Srinivas, S., Buyyounouski, M. K., Chung, B. I., Chertow, G. M., Asch, S. M., Wagner, T. H., Brooks, J. D., Leppert, J. T.
2016; 70 (2): 227-230
 - **Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.**
Balar, A., Galsky, M. D., Loriot, Y., Dawson, N., Necchi, A., Srinivas, S., Joseph, R., Vaishampayan, U. N., Sridhar, S. S., Quinn, D. I., Drakaki, A., Duran, I., Rosenberg, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model** *CLINICAL GENITOURINARY CANCER*
Salah, S., Lee, J., Rozzi, A., Kitamura, H., Matsumoto, K., Srinivas, S., Morales-Barrera, R., Carles, J., Al-Wardat, R., Al-Rabi, K., Maakoseh, M.
2016; 14 (3): 255-260
 - **Second-line chemotherapy in older patients with metastatic urothelial carcinoma: Pooled analysis of 10 second-line studies.**
Salah, S., Lee, J., Rozzi, A., Lewin, J., Kitamura, H., Matsumoto, K., Vis, D. J., Wessels, L. F. A., Srinivas, S., Morales, R., Carles, J., Toubasi, S., Lee, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Prognostic factors for pancreatic metastases in renal cell cancer.**
Chung, A., Li, S., Shah, S., Fan, A. C., Srinivas, S.
AMER SOC CLINICAL ONCOLOGY.2016
 - **An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel.**
Harshman, L., Gray, K. P., Polacek, L., Taplin, M., Choudhury, A., Pomerantz, M. M., Bellmunt, J., Yu, C., Sun, Z., Srinivas, S., Kantoff, P. W., Sweeney, C.
AMER SOC CLINICAL ONCOLOGY.2016
 - **Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC)**
Wells, J., Donskov, F., Fracon, A., Pasini, F., Bjarnason, G. A., Knox, J. J., Beuselinck, B., Rha, S., Agarwal, N., Brugarolas, J., Lee, J., Pal, S. K., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study**

- Motzer, R. J., Sharma, P., Escudier, B. J., McDermott, D. F., George, S., Srinivas, S., Tykodi, S. S., Sosman, J., Plimack, E. R., Nathan, P. D., Gruenewald, V., Tomita, Y., Zhao, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Platinum retreatment in second line chemotherapy for metastatic urothelial carcinoma (UC): Assessing the concept of platinum sensitivity and predictors of survival.**
Ma'koseh, M., Kitamura, H., Srinivas, S., Lewin, J., Salah, S.
AMER SOC CLINICAL ONCOLOGY.2016
 - **The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT).**
Necchi, A., Sonpavde, G., Lo Vullo, S., Bamias, A., Crabb, S. J., Harshman, L., Bellmunt, J., De Giorgi, U., Sternberg, C. N., Ladoire, S., Wong, Y., Yu, E. Y., Chowdhury, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial** *LANCET*
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., Srinivas, S., Retz, M. M., Grivas, et al
2016; 387 (10031): 1909-1920
 - **Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma** *PLOS ONE*
Minamimoto, R., Barkhodari, A., Harshman, L., Srinivas, S., Quon, A.
2016; 11 (4)
 - **Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.** *Journal of cutaneous pathology*
Schaberg, K. B., Novoa, R. A., Wakelee, H. A., Kim, J., Cheung, C., Srinivas, S., Kwong, B. Y.
2016; 43 (4): 339-346
 - **Disparities in Adolescent and Young Adult Survival After Testicular Cancer Vary by Histologic Subtype: A Population-Based Study in California 1988-2010.** *Journal of adolescent and young adult oncology*
DeRouen, M. C., Mujahid, M., Srinivas, S., Keegan, T. H.
2016; 5 (1): 31-40
 - **Consolidative radiotherapy in metastatic urothelial cancer (MUC)**
Srinivas, S., Narayanan, S., Fan, A. C., Hancock, S., Skinner, E. C.
AMER SOC CLINICAL ONCOLOGY.2016
 - **Real world chart review of adverse event management in patients taking tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) by line of therapy (LoT).**
Srinivas, S., Stein, D., Teltsch, D. Y., Tao, S., Ramaswamy, K.
AMER SOC CLINICAL ONCOLOGY.2016
 - **CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).**
Motzer, R. J., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J., Procopio, G., Plimack, E. R., Castellano, D. E., Gurney, H., Donskov, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).**
Morales, J., Wells, J., Donskov, F., Bjarnason, G. A., Lee, J., Knox, J. J., Beuselinck, B., Vaishampayan, U. N., Brugarolas, J., Broom, R., Bamias, A., Yuasa, T., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).**
de Velasco, G., Xie, W., Donskov, F., Albiges, L., Beuselinck, B., Srinivas, S., Agarwal, N., Lee, J., Brugarolas, J., Wood, L., Kollmannsberger, C. K., Rha, S., North, et al
AMER SOC CLINICAL ONCOLOGY.2016

- **Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.**
Davis, I. D., Xie, W., Pezaro, C., Donskov, F., Wells, C., Agarwal, N., Srinivas, S., Yuasa, T., Beuselinck, B., Wood, L., Ernst, D., Kanesvaran, R., Knox, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.** *Nature reviews. Urology*
Narayanan, S., Srinivas, S., Feldman, D.
2016; 13 (1): 47-60
- **Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Mohler, J. L., Armstrong, A. J., Bahnon, R. R., D'Amico, A. V., Davis, B. J., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Hurwitz, M., Kane, C. J., Kawachi, et al
2016; 14 (1): 19-30
- **Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy** *NATURE REVIEWS UROLOGY*
Narayanan, S., Srinivas, S., Feldman, D.
2016; 13 (1): 47-60
- **Real world chart review study of adverse events of special interest (AESI) Management in patients taking tyrosine kinase inhibitors (TKis) to treat metastatic renal cell carcinoma (mRCC)**
Srinivas, S., Stein, D., Teltsch, D., Tao, S., Chen, C., Cisar, L., Ramaswamy, K.
WILEY-BLACKWELL.2015: 20-21
- **CheckMate 025: a randomized, open-label, phase III study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)**
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, et al
WILEY-BLACKWELL.2015: 17
- **First line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium**
Morales, J., Wells, J., Donskov, F., Bjarnason, G. A., Lee, J., Knox, J. J., Beuselinck, B., Vashampayan, U., Brugarolas, J., Broom, R., Koutsoukos, K., Yuasa, T., Srinivas, et al
WILEY-BLACKWELL.2015: 20
- **Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, et al
2015; 373 (19): 1803-1813
- **Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.** *European urology*
Kroeger, N., Pantuck, A. J., Wells, J. C., Lawrence, N., Broom, R., Kim, J. J., Srinivas, S., Yim, J., Bjarnason, G. A., Templeton, A., Knox, J., Bernstein, E., Smoragiewicz, et al
2015; 68 (3): 506-515
- **Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies** *EUROPEAN UROLOGY*
Kroeger, N., Pantuck, A. J., Wells, J. C., Lawrence, N., Broom, R., Kim, J. J., Srinivas, S., Yim, J., Bjarnason, G. A., Templeton, A., Knox, J., Bernstein, E., Smoragiewicz, et al
2015; 68 (3): 506-515
- **Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)**
Heng, D., Stukalin, I., Wells, C., Donskov, F., Rini, B. I., Lee, J., Bjarnason, G. A., Beuselinck, B., Smoragiewicz, M., Alva, A., Srinivas, S., Wood, L., Brugarolas, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Prognostic features for testicular cancers (TCs): Can this be gleaned from pathology reports?**
Srinivas, S., Eisenberg, M., Skinner, E. C.
AMER SOC CLINICAL ONCOLOGY.2015

- **Evaluation of FDG PET/CT measurement parameters for prediction of the prognosis after Sunitinib Therapy in Renal Cell Carcinoma**
Minamimoto, R., Barkhodari, A., Harshman, L., Quon, A., Srinivas, S.
SOC NUCLEAR MEDICINE INC.2015
- **Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium.** *Clinical genitourinary cancer*
Kyriakopoulos, C. E., Chittoria, N., Choueiri, T. K., Kroeger, N., Lee, J., Srinivas, S., Knox, J. J., Bjarnason, G. A., Ernst, S. D., Wood, L. A., Vaishampayan, U. N., Agarwal, N., Pal, et al
2015; 13 (2): e79-85
- **Second-Line Therapies in Metastatic Urothelial Carcinoma** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Narayanan, S., Harshman, L. C., Srinivas, S.
2015; 29 (2): 341-?
- **The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.** *The Lancet. Oncology*
Ko, J. J., Xie, W., Kroeger, N., Lee, J., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., Smoragiewicz, M., Donskov, F., Kanesvaran, et al
2015; 16 (3): 293-300
- **Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.**
Srinivas, S., Narayanan, S., Harshman, L., Pachynski, R., Lam, A. P., Fan, A. C., Poushnejad, S., Haas, D., Vaishampayan, U. N.
AMER SOC CLINICAL ONCOLOGY.2015
- **Second-line chemotherapy for metastatic urothelial cell carcinoma: Pooled analysis and construction of a prognostic model.**
Salah, S., Lee, J., Rozzi, A., Kitamura, H., Matsumoto, K., Srinivas, S., Morales, R., Carles, J., Al-Wardat, R., Maakoseh, M.
AMER SOC CLINICAL ONCOLOGY.2015
- **Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.**
Heng, D., Wells, C., Donskov, F., Rini, B. I., Lee, J., Bjarnason, G. A., Beuselinck, B., Smoragiewicz, M., Alva, A., Srinivas, S., Wood, L., Yamamoto, H., Ernst, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Exploring the effect of medication features in renal cell carcinoma: A patient preference study**
Srinivas, S., Mansfield, C., Sandin, R., Hauber, A., Hariharan, S., Matczak, E., Pugh, A., Chen, C.
AMER SOC CLINICAL ONCOLOGY.2015
- **New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?** *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*
Wilson, L., Tang, J., Zhong, L., Balani, G., Gipson, G., Xiang, P., Yu, D., Srinivas, S.
2014; 20 (6): 417-425
- **New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?** *JOURNAL OF ONCOLOGY PHARMACY PRACTICE*
Wilson, L., Tang, J., Zhong, L., Balani, G., Gipson, G., Xiang, P., Yu, D., Srinivas, S.
2014; 20 (6): 417-425
- **First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium** *CLINICAL GENITOURINARY CANCER*
Harshman, L. C., Kroeger, N., Rha, S. Y., Donskov, F., Wood, L., Tantravahi, S. K., Vaishampayan, U., Rini, B. I., Knox, J., North, S., Ernst, S., Yuasa, T., Srinivas, et al
2014; 12 (5): 335-340
- **Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium** *EUROPEAN UROLOGY*
Heng, D. Y., Wells, J. C., Rini, B. I., Beuselinck, B., Lee, J., Knox, J. J., Bjarnason, G. A., Pal, S. K., Kollmannsberger, C. K., Yuasa, T., Srinivas, S., Donskov, F., Bamias, et al
2014; 66 (4): 704-710
- **A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma** *CANCER*

- Hussain, M., Daignault, S., Agarwal, N., Grivas, P. D., Siefker-Radtke, A. O., Puzanov, I., MacVicar, G. R., Levine, E. G., Srinivas, S., Twardowski, P., Eisenberger, M. A., Quinn, D. I., Vaishampayan, et al
2014; 120 (17): 2684-2693
- **A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.** *Clinical genitourinary cancer*
Alimohamed, N., Lee, J., Srinivas, S., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., Wood, L., Vaishampayan, U. N., Tan, M., Rha, S. Y., Donskov, F., Tantravahi, S., Kollmannsberger, et al
2014; 12 (4): e127-31
 - **Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy** *EUROPEAN UROLOGY*
Kroeger, N., Choueiri, T. K., Lee, J., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., Wood, L., Srinivas, S., Vaishampayan, U. N., Rha, S., Pal, S. K., Yuasa, T., Donskov, et al
2014; 65 (6): 1086-1092
 - **The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium**
Albiges, L., Xie, W., Lee, J., Rini, B. I., Srinivas, S., Bjarnason, G. A., Ernst, D., Wood, L., Vaishampayan, U. N., Rha, S., Agarwal, N., Yuasa, T., Pal, et al
AMER SOC CLINICAL ONCOLOGY.2014
 - **Timing of angiotensin system inhibitor use and overall survival in patients on tyrosine kinase inhibitors for renal cell carcinoma**
Lam, A. P., Allen, J., Srinivas, S.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Prostate cancer, version 2.2014.** *Journal of the National Comprehensive Cancer Network*
Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., D'Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Kane, C. J., Kawachi, et al
2014; 12 (5): 686-718
 - **Combined NaF/FDG PET/CT evaluation of prostate cancer patients**
Iagaru, A., Mosci, C., Keu, K., Mittra, E., Hancock, S., Pachynski, R., Srinivas, S., Gambhir, S.
SOC NUCLEAR MEDICINE INC.2014
 - **Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.** *International journal of cancer. Journal international du cancer*
Conti, S. L., Thomas, I., Hagedorn, J. C., Chung, B. I., Chertow, G. M., Wagner, T. H., Brooks, J. D., Srinivas, S., Leppert, J. T.
2014; 134 (9): 2245-2252
 - **KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells** *INTERNATIONAL JOURNAL OF CANCER*
Conti, S. L., Thomas, I., Hagedorn, J. C., Chung, B. I., Chertow, G. M., Wagner, T. H., Brooks, J. D., Srinivas, S., Leppert, J. T.
2014; 134 (9): 2245-2252
 - **First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.** *British journal of cancer*
Ko, J. J., Choueiri, T. K., Rini, B. I., Lee, J., Kroeger, N., Srinivas, S., Harshman, L. C., Knox, J. J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Vaishampayan, U. N., Agarwal, et al
2014; 110 (8): 1917-1922
 - **The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the international metastatic renal cell cancer database consortium.** *European urology*
Schutz, F. A., Xie, W., Donskov, F., Sircar, M., McDermott, D. F., Rini, B. I., Agarwal, N., Pal, S. K., Srinivas, S., Kollmannsberger, C., North, S. A., Wood, L. A., Vaishampayan, et al
2014; 65 (4): 723-730
 - **Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma Reply** *UROLOGY*
Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Brooks, J. D., Srinivas, S., Chertow, G. M., Saigal, C. S.
2014; 83 (4): 779-780
 - **Utilization of renal mass biopsy in patients with renal cell carcinoma.** *Urology*
Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Srinivas, S., Chertow, G. M., Brooks, J. D., Saigal, C. S.

2014; 83 (4): 774-780

● **Reply. Urology**

Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Brooks, J. D., Srinivas, S., Chertow, G. M., Saigal, C. S.

2014; 83 (4): 779-780

● **Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. European urology**

McKay, R. R., Kroeger, N., Xie, W., Lee, J., Knox, J. J., Bjarnason, G. A., Mackenzie, M. J., Wood, L., Srinivas, S., Vaishampayan, U. N., Rha, S., Pal, S. K., Donskov, et al

2014; 65 (3): 577-584

● **Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)**

Heng, D., Rini, B. I., Beuselinck, B., Lee, J., Knox, J. J., Bjarnason, G. A., Pal, S., Kollmannsberger, C. K., Yuasa, T., Srinivas, S., Donskov, F., Bamias, A., Wood, et al

AMER SOC CLINICAL ONCOLOGY.2014

● **Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC).**

Srinivas, S., Narayanan, S., Harshman, L., Lam, A. P., Vaishampayan, U. N., Haas, D., Poushnejad, S., Pachynski, R.

AMER SOC CLINICAL ONCOLOGY.2014

● **Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT)**

Templeton, A. J., Heng, D., Choueiri, T. K., McDermott, D. F., Fay, A. P., Srinivas, S., Harshman, L., Beuselinck, B., Smoragiewicz, M., Kim, J. J., Knox, J. J.

AMER SOC CLINICAL ONCOLOGY.2014

● **Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of oncology**

Heng, D. Y., Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., Pal, S. K., Srinivas, S., Bjarnason, G. A., Knox, J. J., MacKenzie, M., Vaishampayan, U. N., Tan, M. H., Rha, et al

2014; 25 (1): 149-154

● **Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK**

Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., D'Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Kawachi, M. H., Kuettel, et al

2013; 11 (12): 1471-1479

● **Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network**

Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., D'Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Kawachi, M. H., Kuettel, et al

2013; 11 (12): 1471-1479

● **Utilization of renal mass biopsy in patients with renal cell carcinoma 12th International Kidney Cancer Symposium**

Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Srinivas, S., Chertow, G. M., Brooks, J. D., Saigal, C. S.

WILEY-BLACKWELL.2013: 14-14

● **Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era 12th International Kidney Cancer Symposium**

Conti, S. L., Thomas, I., Hagedorn, J. C., Chung, B. I., Chertow, G. M., Wagner, T. H., Brooks, J. D., Srinivas, S., Leppert, J. T.

WILEY-BLACKWELL.2013: 14-16

● **Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma EUROPEAN JOURNAL OF CANCER**

Fishman, M. N., Srinivas, S., Hauke, R. J., Amato, R. J., Esteves, B., Cotreau, M. M., Strahs, A. L., Slichenmyer, W. J., Bhargava, P., Kabbinavar, F. F.

2013; 49 (13): 2841-2850

● **Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial CANCER IMMUNOLOGY IMMUNOTHERAPY**

Harrop, R., Chu, F., Gabrail, N., Srinivas, S., Blount, D., Ferrari, A.

2013; 62 (9): 1511-1520

- **Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria** *CANCER*
Kroeger, N., Xie, W., Lee, J., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., Wood, L., Srinivas, S., Vaishamayan, U. N., Rha, S., Pal, S. K., Yuasa, T., Donskov, et al
2013; 119 (16): 2999-3006
- **A randomized, double-blind, placebo-controlled, Phase II study with and without enzalutamide in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer** *INVESTIGATIONAL NEW DRUGS*
Dreicer, R., Garcia, J., Rini, B., Vogelzang, N., Srinivas, S., Somer, B., Shi, P., Kania, M., Raghavan, D.
2013; 31 (4): 1044-1050
- **NCCN Task Force Report: Bone Health in Cancer Care** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., Van Poznak, C. H.
2013; 11: S1-S50
- **NCCN Task Force Report: Bone Health In Cancer Care.** *Journal of the National Comprehensive Cancer Network*
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., Van Poznak, C. H.
2013; 11: S1-50
- **A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma.** *Clinical genitourinary cancer*
Harshman, L. C., Barbeau, S., McMillian, A., Srinivas, S.
2013; 11 (2): 100-106
- **Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis** *PLOS ONE*
Zhong, L., Pon, V., Srinivas, S., Nguyen, N., Frear, M., Kwon, S., Gong, C., Malmstrom, R., Wilson, L.
2013; 8 (5)
- **First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC)**
Heng, D., Rini, B. I., Lee, J., Kroeger, N., Srinivas, S., Harshman, L., Knox, J. J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Vaishampayan, U. N., Agarwal, N., Pal, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).**
Harshman, L., Kroeger, N., Rha, S., Donskov, F., Wood, L., Tantravahi, S., Vaishampayan, U. N., Rini, B. I., Knox, J. J., North, S. A., MacKenzie, M. J., Yuasa, T., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium**
Chittoria, N., Zhu, H., Choueiri, T. K., Kroeger, N., Lee, J., Srinivas, S., Knox, J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Vaishampayan, U. N., Agarwal, N., Pal, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy**
Kroeger, N., Lee, J., Bjarnason, G. A., Knox, J. J., MacKenzie, M. J., Vaishampayan, U. N., Wood, L., Srinivas, S., Rha, S., Pal, S., Yuasa, T., Donskov, F., Agarwal, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)** *UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS*
Harshman, L. C., Yu, R. J., Allen, G. I., Srinivas, S., Gill, H. S., Chung, B. I.
2013; 31 (3): 379-385
- **TEMPORAL TRENDS IN UTILIZATION OF CYTOREDUCTIVE NEPHRECTOMY AND PATIENT SURVIVAL IN THE TARGETED THERAPY ERA** *Annual Meeting of the American-Urological-Association (AUA)*
Conti, S. L., Hagedorn, J., Chung, B. I., Srinivas, S., Leppert, J.
ELSEVIER SCIENCE INC.2013: E753-E753

- **NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC**
Leppert, J., Fan, A., Liliental, J., Xu, L., Thong, A., Yost, C., Yaghi, A., Metzner, T., Brooks, J., Harshman, L., Sabatti, C., Srinivas, S., Felsher, et al
ELSEVIER SCIENCE INC.2013: E246–E247
- **Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC)**
McKay, R. R., Kroeger, N., Xie, W., Lee, J., Knox, J. J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishampayan, U. N., Rha, S., Pal, S., Donskov, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes**
Kroeger, N., Xie, W., Lee, J., Bjarnason, G. A., Knox, J. J., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishamayan, U. N., Rha, S., Pal, S., Donskov, F., Agarwal, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC**
Fan, A. C., Leppert, J., Liliental, J. E., Xu, L., Thong, A. E., Yost, C., Yaghi, A., Brooks, J. D., Harshman, L., Sabatti, C., Srinivas, S., Felsher, D. W.
AMER SOC CLINICAL ONCOLOGY.2013
- **Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes**
Kroeger, N., Xie, W., Lee, J., Bjarnason, G. A., Knox, J. J., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishamayan, U. N., Rha, S., Pal, S., Donskov, F., Agarwal, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial** *JOURNAL OF CLINICAL ONCOLOGY*
Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., Vaishampayan, U. N., Haas, N. B., Spira, et al
2013; 31 (4): 412-419
- **The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients** *JACC-HEART FAILURE*
Hall, P. S., Harshman, L. C., Srinivas, S., Witteles, R. M.
2013; 1 (1): 72-78
- **The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients.** *JACC. Heart failure*
Hall, P. S., Harshman, L. C., Srinivas, S., Witteles, R. M.
2013; 1 (1): 72-78
- **Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma** *JOURNAL OF CLINICAL ONCOLOGY*
Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., Ottesen, L. H., Laubscher, K. H., Sherman, et al
2013; 31 (2): 181-186
- **Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone** *CLINICAL CANCER RESEARCH*
Ryan, C. J., Rosenthal, M., Ng, S., Alumkal, J., Picus, J., Gravis, G., Fizazi, K., Forget, F., Machiels, J., Srinivas, S., Zhu, M., Tang, R., Oliner, et al
2013; 19 (1): 215-224
- **mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer** *PLOS ONE*
Cann, G. M., Gulzar, Z. G., Cooper, S., Li, R., Luo, S., Tat, M., Stuart, S., Schroth, G., Srinivas, S., Ronaghi, M., Brooks, J. D., Talasz, A. H.
2012; 7 (11)
- **Variations in Normal Serum Alpha-Fetoprotein (AFP) Levels in Patients with Testicular Cancer on Surveillance** *ONKOLOGIE*
Patel, P., Balise, R., Srinivas, S.
2012; 35 (10): 588-591

- **Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study** *LANCET ONCOLOGY*
Harshman, L. C., Xie, W., Bjarnason, G. A., Knox, J. J., MacKenzie, M., Wood, L., Srinivas, S., Vaishampayan, U. N., Tan, M., Rha, S., Donskov, F., Agarwal, N., Kollmannsberger, et al
2012; 13 (9): 927-935
- **Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Mohler, J. L., Armstrong, A. J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T., Higano, C. S., Horwitz, E. M., Kantoff, P. W., Kawachi, et al
2012; 10 (9): 1081-1087
- **Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies.** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Hall, P. S., Witteles, R., Srinivas, S., Harshman, L. C.
AMER SOC CLINICAL ONCOLOGY.2012
- **Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis.** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Zhong, L., Srinivas, S., Pon, V., Nicole Nguyen, N., Frear, M., Kwan, S., Gong, C., Malmstrom, R., Loucks, A., Wilson, L.
AMER SOC CLINICAL ONCOLOGY.2012
- **Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).**
Grivas, P., Agarwal, N., Siefker-Radtke, A. O., Daignault, S., Puzanov, I., MacVicar, G. R., Levine, E., Srinivas, S., Twardowski, P., Eisenberger, M. A., Quinn, D. I., Vaishampayan, U. N., Yu, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Evaluation of ERCC1 and RRM1 as prognostic biomarkers in urothelial cancer (UC) treated with adjuvant platinum and gemcitabine chemotherapy.** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Harshman, L. C., Bepler, G., Quinn, D. I., McKenney, J., Hawes, D., Simon, N., Srinivas, S., Dorff, T. B.
AMER SOC CLINICAL ONCOLOGY.2012
- **Phase 1 trial of tivozanib (AV-951) combined with temsirolimus in patients with renal cell carcinoma** *10th International Kidney Cancer Symposium*
Srinivas, S., Kabbinavar, F. F., Hauke, R. J., Esteves, B., Cotreau, M. M., Strahs, A. L., Fishman, M. N.
WILEY-BLACKWELL.2012: 10–11
- **Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).**
Srinivasan, R., Bottaro, D. P., Choueiri, T. K., Vaishampayan, U. N., Rosenberg, J. E., Logan, T., Harzstark, A., Rini, B. I., Srinivas, S., Adams, L. M., Laubscher, K., Ottesen, L., McDermott, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.**
Choueiri, T. K., Vaishampayan, U. N., Rosenberg, J. E., Logan, T., Harzstark, A., Rini, B. I., Srinivas, S., Adams, L. M., Sherman, L., Ottesen, L., McDermott, D. F., Bottaro, D. P., Linehan, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease** *INVESTIGATIONAL NEW DRUGS*
Dreicer, R., Garcia, J., Hussain, M., Rini, B., Vogelzang, N., Srinivas, S., Somer, B., Zhao, Y. D., Kania, M., Raghavan, D.
2011; 29 (6): 1441-1448
- **Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer** *UROLOGY*
Oh, W. K., Galsky, M. D., Stadler, W. M., Srinivas, S., Chu, F., Bublely, G., Goddard, J., Dunbar, J., Ross, R. W.
2011; 78 (3): 626-630
- **Toxicities of targeted agents in advanced renal cell carcinoma.** *Current clinical pharmacology*
Patel, P., Srinivas, S.

2011; 6 (3): 181-188

- **Pyoderma Gangrenosum With the Use of Sunitinib** *JOURNAL OF CLINICAL ONCOLOGY*
Nadauld, L. D., Miller, M. B., Srinivas, S.
2011; 29 (10): E266-E267
- **NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Hudes, G. R., Carducci, M. A., Choueiri, T. K., Esper, P., Jonasch, E., Kumar, R., Margolin, K. A., Michaelson, D., Motzer, R. J., Pili, R., Roethke, S., Srinivas, S.
2011; 9: S1-S29
- **NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy** *J Natl Compr Canc Network*
Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, KumarR, Margolin KA, Michaelson D, Motzer RJ, Pili P, Roethke S, Srinivas S
2011; 9: 29
- **Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients** *BJU INTERNATIONAL*
Harshman, L. C., Bepler, G., Zheng, Z., Higgins, J. P., Allen, G. I., Srinivas, S.
2010; 106 (11): 1805-1811
- **Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC** *CLINICAL CANCER RESEARCH*
Pili, R., Rosenthal, M. A., Mainwaring, P. N., van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J., Wong, S., Clingan, P.
2010; 16 (10): 2906-2914
- **NCCN clinical practice guidelines in oncology: prostate cancer.** *Journal of the National Comprehensive Cancer Network*
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., Kantoff, P., Kawachi, M., Kuettel, et al
2010; 8 (2): 162-200
- **Prostate Cancer** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., Kantoff, P., Kawachi, M., Kuettel, et al
2010; 8 (2): 162-200
- **The bevacizumab experience in advanced renal cell carcinoma** *ONCOTARGETS AND THERAPY*
Harshman, L. C., Srinivas, S.
2010; 3: 179-189
- **Formulating the Question and Objectives** *ONCOLOGY CLINICAL TRIALS*
Harshman, L. C., Srinivas, S., Symanowski, J., Vogelzang, N. J.
edited by Kelly, W. K., Halabi, S.
2010: 29-34
- **Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer** *Open Prostate Cancer Journal*
Bazan JG, King CR, Brooks JD, Srinivas S
2010; 3: 99-104
- **RRM1 expression in muscle invasive, locally advanced urothelial cancer is associated with survival in younger patients** *Annual Meeting of the EORTC/NCI/ASCO on Molecular Markers in Cancer*
Harshman, L., Bepler, G., Zheng, Z., Higgins, J., Allen, G., Srinivas, S.
PERGAMON-ELSEVIER SCIENCE LTD.2009: 19-19
- **Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma** *14th European Cancer Conference (ECCO 14)*
Escudier, B., Roigas, J., Gillessen, S., Harmenberg, U., Srinivas, S., Mulder, S. F., Fountzilias, G., Peschel, C., Flodgren, P., Maneval, E. C., Chen, I., Vogelzang, N. J.
AMER SOC CLINICAL ONCOLOGY.2009: 4068-75

- **A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer** *3rd International Symposium on Vitamin D Analogs in Cancer Prevention and Therapy*
Srinivas, S., Feldman, D.
INT INST ANTICANCER RESEARCH.2009: 3605–10
- **Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib** *NATURE REVIEWS UROLOGY*
Harshman, L. C., Srinivas, S., Kamaya, A., Chung, B. I.
2009; 6 (6): 338-343
- **NCCN Task Force Report: Bone Health in Cancer Care** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R. N., Shapiro, C. L., Shields, A., Smith, M. R., Srinivas, S., Van Poznak, C. H.
2009; 7: S1-S32
- **Correlation of RRM1 expression in muscle invasive locally advanced urothelial cancer with age** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Harshman, L. C., Bepler, G., Zheng, Z., Higgins, J. P., ALLEN, G. I., Tibshirani, R., Srinivas, S.
AMER SOC CLINICAL ONCOLOGY.2009
- **Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer** *Dermato Endocrinology*
Krishnan AV, Srinivas S, Feldman D
2009; 1: 7-11
- **A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma** *CHEMOTHERAPY*
Srinivas, S., Harshman, L. C.
2009; 55 (5): 321-326
- **Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma** *CANCER INVESTIGATION*
Harshman, L. C., Kuo, C. J., Wong, B. Y., Vogelzang, N. J., Srinivas, S.
2009; 27 (8): 851-856
- **High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience.** *Bone Marrow Transplant*
Agarwal R, Dvorak CC, Stockerl- Goldstein KE, Johnson L, Srinivas S
2009; 43 (7): 547-52
- **Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer.** *Dermato-endocrinology*
Krishnan, A. V., Srinivas, S., Feldman, D.
2009; 1 (1): 7-11
- **Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Harshman, L. C., Kuo, C. J., Wong, B. Y., Vogelzang, N. J., Srinivas, S.
AMER SOC HEMATOLOGY.2008: 1185–85
- **The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma - Is Not the Answer** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Harshman, L. C., Li, M., Srinivas, S.
2008; 31 (5): 417-423
- **Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate** *ANNALS OF ONCOLOGY*
Telli, M. L., Witteles, R. M., Fisher, G. A., Srinivas, S.
2008; 19 (9): 1613-1618
- **Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma** *CANCER*
Jonasch, E., Stadler, W. M., Bukowski, R. M., Hayes, T. G., Varadhachary, A., Malik, R., Figlin, R. A., Srinivas, S.
2008; 113 (1): 72-77
- **Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC)**
Harshman, L. C., Kuo, C. J., Srinivas, S.
AMER SOC CLINICAL ONCOLOGY.2008

- **Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer** *ONKOLOGIE*
Harshman, L., Srinivas, S.
2008; 31 (8-9): 432-433
- **Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma** *EXPERT REVIEW OF ANTICANCER THERAPY*
Harshman, L. C., Srinivas, S.
2007; 7 (12): 1749-1761
- **A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)**
Ross, R. W., Srinivasan, R., Vaishampayan, U., Bukowski, R., Rosenberg, J., Eisenberg, P., Logan, T., Srinivas, S., Stein, M., Mueller, T., Keer, H. N.
AMER ASSOC CANCER RESEARCH.2007: 3511S-3511S
- **Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K., Srinivas, S., Vaishampayan, U., Drabkin, H. A., Dutcher, J., Ryba, S., Xia, Q., Scappaticci, F. A., McDermott, D.
AMER SOC CLINICAL ONCOLOGY.2007: 4536-41
- **Acute pancreatitis associated with sorafenib** *SOUTHERN MEDICAL JOURNAL*
Li, M., Srinivas, S.
2007; 100 (9): 909-911
- **Prostate cancer. Clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Mohler, J., Babaian, R. J., Bahnson, R. R., Boston, B., D'Amico, A., Eastham, J. A., Hauke, R. J., Huben, R. P., Kantoff, P., Kawachi, M., Kuettel, M., Lange, P. H., Logothetis, et al
2007; 5 (7): 650-683
- **Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer** *Conference on Vitamin D and Cancer - Current Dilemmas/ Future Needs*
Feldman, D., Krishnan, A., Moreno, J., Swami, S., Peehl, D. M., Srinivas, S.
BLACKWELL PUBLISHING.2007: S113-S115
- **Bone related events in high risk prostate cancer** *JOURNAL OF UROLOGY*
Srinivas, S., Colocci, N.
2006; 176 (6): S50-S54
- **Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade** *UROLOGY*
King, C. R., McNeal, J. E., Gill, H., Brooks, J. D., Srinivas, S., Presti, J. C.
2006; 67 (6): 1229-1234
- **Nonplatinum therapy in advanced bladder cancer** *EXPERT REVIEW OF ANTICANCER THERAPY*
Srinivas, S., Colocci, N.
2006; 6 (6): 887-894
- **Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer** *UROLOGY*
Srinivas, S., Krishnan, A. V., Colocci, N., Feldman, D.
2006; 67 (5): 1001-1006
- **Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy** *UROLOGIA INTERNATIONALIS*
Liu, I. J., Lai, Y., Espiritu, J. I., Segall, G. M., Srinivas, S., Nino-Murcia, M., Terris, M. K.
2006; 77 (1): 69-75
- **Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC)**
Escudier, B., Roigas, J., Gillessen, S., Srinivas, S., Pisa, P., Vogelzang, N., Fountzilas, G., Peschel, C., Baum, C. M., De Mulder, P.
OXFORD UNIV PRESS.2006: 144
- **Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment.** *Journal of clinical oncology*
Badger, J., Kang, S., Uzieblo, A., Srinivas, S.

2005; 23 (28): 7224-7225

- **Case 3. Photo therapy recall with gemcitabine following ultraviolet B treatment** *JOURNAL OF CLINICAL ONCOLOGY*
Badger, J., Uzieblo, A., Srinivas, S., Kang, S. W.
2005; 23 (28): 7224-7225
- **A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma** *BJU INTERNATIONAL*
Srinivas, S., Guardino, A. E.
2005; 96 (4): 536-539
- **A nonplatinum combination in metastatic transitional cell carcinoma** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Srinivas, S., Guardino, A. E.
2005; 28 (2): 114-118
- **Node Positive Bladder Cancer** *Arab J Urology*
Srinivas S, Freiha F
2005; 3: 7-11
- **Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis** *UROLOGY*
Morgan, K., Srinivas, S., Freiha, F. S.
2004; 64 (4)
- **Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies.** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Srinivas, S., Guardino, A. E.
AMER SOC CLINICAL ONCOLOGY.2004: 425S-425S
- **Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily** *JOURNAL OF ANDROLOGY*
Murphy, J. C., Srinivas, S., Terris, M. K.
2004; 25 (4): 630-634
- **Positron emission tomography in the initial staging of esophageal cancer** *73rd Annual Meeting of the Pacific-Coast-Surgical-Association*
Wren, S. M., Stijns, P., Srinivas, S.
AMER MEDICAL ASSOC.2002: 1001-6
- **Utility of bone scan post primary therapy in prostate cancer** *UroOncology*
Srinivas S
2002; 2: 37-39
- **Management choices in stage I non-seminomatous Germ Cell Tumor** *UroOncology*
Srinivas S, Terris MK
2001; 1: 1-4
- **Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer** *95th Annual Meeting of the American-Urological-Association*
Kiratli, B. J., Srinivas, S., Perakash, I., Terris, M. K.
ELSEVIER SCIENCE INC.2001: 127-32
- **High-dose chemotherapy in poor-risk germ-cell tumors** *ONCOLOGY-NEW YORK*
Srinivas, S.
2000; 14 (10): 1419-1423
- **Spontaneous pneumothorax in malignancy: A case report and review of the literature** *ANNALS OF ONCOLOGY*
Srinivas, S., Varadhachary, G.
2000; 11 (7): 887-889
- **Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer.** *Clinical positron imaging : official journal of the Institute for Clinical P.E.T*
Durski, J. M., Srinivas, S., Segall, G.
2000; 3 (3): 97-105

- **Actinomycin D revisited in testicular cancer. A case report** *TUMORI*
Srinivas, S., Freiha, F. S.
1999; 85 (1): 78-79
- **Tool support for authoring eligibility criteria for cancer trials** *Annual Symposium of the American-Medical-Informatics-Association*
Rubin, D. L., Gennari, J. H., Srinivas, S., Yuen, A., Kaizer, H., Musen, M. A., Silva, J. S.
BMJ PUBLISHING GROUP.1999: 369-373
- **Methotrexate tolerance in patients with ileal conduits and continent diversions** *CANCER*
Srinivas, S., Mahalati, K., Freiha, F. S.
1998; 82 (6): 1134-1136
- **Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Small, E. J., Srinivas, S., Egan, B., McMillan, A., Rearden, T. P.
1996; 14 (5): 1617-1625
- **THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTATE CANCER** *CANCER*
Small, E. J., Srinivas, S.
1995; 76 (8): 1428-1434
- **THE WEIGHT-BASED HEPARIN DOSING NOMOGRAM COMPARED WITH A STANDARD CARE NOMOGRAM - A RANDOMIZED CONTROLLED TRIAL** *ANNALS OF INTERNAL MEDICINE*
Raschke, R. A., Reilly, B. M., Guidry, J. R., Fontana, J. R., Srinivas, S.
1993; 119 (9): 874-881
- **INTRAVENOUS HEPARIN DOSING - PATTERNS AND VARIATIONS IN INTERNISTS PRACTICES** *JOURNAL OF GENERAL INTERNAL MEDICINE*
Reilly, B. M., Raschke, R., Srinivas, S., Nieman, T.
1993; 8 (10): 536-542